Compare JDZG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JDZG | EVAX |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | China | Denmark |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 31.9M |
| IPO Year | 2023 | 2020 |
| Metric | JDZG | EVAX |
|---|---|---|
| Price | $1.30 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 2.4M | 22.0K |
| Earning Date | 04-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $1.25 |
| 52 Week High | $4.06 | $12.15 |
| Indicator | JDZG | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 59.38 |
| Support Level | $1.17 | $2.64 |
| Resistance Level | $1.57 | $4.58 |
| Average True Range (ATR) | 0.16 | 0.31 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 7.48 | 69.17 |
Jiade Ltd specializes in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platform and auxiliary solutions. Auxiliary solutions encompass exam administration services and teaching support services throughout the entire teaching cycle. Specifically, the company offers pre-enrollment guidance on school/major selection and application strategy development, training for entrance exams, and assistance in the application process. The company also provides offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance included in the one-stop comprehensive education supporting services in the People's Republic of China.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.